4.7 Article

White matter atrophy in cerebral amyloid angiopathy

Journal

NEUROLOGY
Volume 95, Issue 5, Pages E554-E562

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000010017

Keywords

-

Funding

  1. NIH [NINDS NS083711, NINDS NS070834]
  2. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. Canadian Institutes of Health Research
  6. AbbVie
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Araclon Biotech
  10. BioClinica, Inc.
  11. Biogen
  12. Bristol-Myers Squibb Company
  13. CereSpir, Inc.
  14. Cogstate
  15. Eisai Inc.
  16. Elan Pharmaceuticals, Inc.
  17. Eli Lilly and Company
  18. EuroImmun
  19. F. Hoffmann-La Roche Ltd.
  20. Genentech, Inc.
  21. Fujirebio
  22. GE Healthcare
  23. IXICO Ltd.
  24. Janssen Alzheimer Immunotherapy Research & Development, LLC
  25. Johnson & Johnson Pharmaceutical Research & Development LLC
  26. Lumosity
  27. Lundbeck
  28. Merck Co., Inc.
  29. Meso Scale Diagnostics, LLC
  30. NeuroRx Research
  31. Neurotrack Technologies
  32. Novartis Pharmaceuticals Corporation
  33. Pfizer Inc.
  34. Piramal Imaging
  35. Servier
  36. Takeda Pharmaceutical Company
  37. Transition Therapeutics
  38. Alzheimer's Disease Neuroimaging Initiative (ADNI) (NIH) [U01 AG024904]
  39. NIH

Ask authors/readers for more resources

Objective We postulated that cerebral amyloid angiopathy (CAA) is associated with white matter atrophy (WMA) and that WMA can be related to cognitive changes in CAA. Methods White matter volume expressed as percent of intracranial volume (pWMV) of prospectively enrolled patients without dementia diagnosed with probable CAA was compared to age-matched healthy controls (HC) and patients with Alzheimer disease (AD). Cognitive scores were also sought to understand the potential effects of WMA on cognitive function. Results Patients with CAA (n = 72) had significantly lower pWMV (27.97% +/- 2.63) when compared to age-matched HC (n = 72; mean difference [MD], 2.38%;p< 0.0001) and patients with AD (n = 72; MD, 1.57%;p< 0.0001). Differences were most pronounced in the posterior occipital regions in both comparisons. When comparisons were restricted to groups of patients with CAA but no intracerebral hemorrhage (n = 32) or hypertension (n = 32), and age-matched HC and AD, the significant differences were unaltered. Within the CAA cohort, higher age, lobar microbleed counts, and presence of hypertension were associated with lower pWMV (p= 0.0007,p= 0.031, andp= 0.003, respectively). All associations remained independent in multivariable analyses. Within the CAA cohort, higher pWMV independently correlated with better scores of executive function. Conclusions Patients with CAA show WMA when compared to age-matched HC and patients with AD. WMA independently correlates with the number of lobar microbleeds, a marker of CAA severity. Consistent spatial patterns of WMA especially in posterior regions might be related to CAA. The association between WMA and measures of executive function suggests that WMA might represent an important mediator of CAA-related neurologic dysfunction.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available